Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production

Oyarzun, Patricio and Kobe, Bostjan (2016) Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production. Human Vaccines and Immunotherapeutics, 12 3: 763-767. doi:10.1080/21645515.2015.1094595


Author Oyarzun, Patricio
Kobe, Bostjan
Title Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production
Journal name Human Vaccines and Immunotherapeutics   Check publisher's open access policy
ISSN 2164-5515
2164-554X
Publication date 2016-01-01
Sub-type Article (original research)
DOI 10.1080/21645515.2015.1094595
Open Access Status Not Open Access
Volume 12
Issue 3
Start page 763
End page 767
Total pages 5
Place of publication New York, NY, United States
Publisher Taylor & Francis
Language eng
Formatted abstract
Novel vaccination approaches based on rational design of B- and T-cell epitopes - epitope-based vaccines - are making progress in the clinical trial pipeline. The epitope-focused recombinant protein-based malaria vaccine (termed RTS,S) is a next-generation approach that successfully reached phase-III trials, and will potentially become the first commercial vaccine against a human parasitic disease. Progress made on methods such as recombinant DNA technology, advanced cell-culture techniques, immunoinformatics and rational design of immunogens are driving the development of these novel concepts. Synthetic recombinant proteins comprising both B- and T-cell epitopes can be efficiently produced through modern biotechnology and bioprocessing methods, and can enable the induction of large repertoires of immune specificities. In particular, the inclusion of appropriate CD4+ T-cell epitopes is increasingly considered a key vaccine component to elicit robust immune responses, as suggested by results coming from HIV-1 clinical trials. In silico strategies for vaccine design are under active development to address genetic variation in pathogens and several broadly protective “universal” influenza and HIV-1 vaccines are currently at different stages of clinical trials. Other methods focus on improving population coverage in target populations by rationally considering specificity and prevalence of the HLA proteins, though a proof-of-concept in humans has not been demonstrated yet. Overall, we expect immunoinformatics and bioprocessing methods to become a central part of the next-generation epitope-based vaccine development and production process.
Keyword CD4+ T-cell epitopes
Epitope-based vaccines
Immunoinformatics
In-silico vaccine design
Recombinant protein vaccines
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Chemistry and Molecular Biosciences
Institute for Molecular Bioscience - Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 09 Oct 2015, 20:45:44 EST by Mrs Louise Nimwegen on behalf of School of Chemistry & Molecular Biosciences